{"id":509670,"date":"2021-07-06T08:04:13","date_gmt":"2021-07-06T12:04:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/"},"modified":"2021-07-06T08:04:13","modified_gmt":"2021-07-06T12:04:13","slug":"lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/","title":{"rendered":"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SALT LAKE CITY<\/span>, July 6, 2021<\/span> \/PRNewswire\/ —\u00a0Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually. Presentation details are below.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Lipocine
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Ladenburg Thalmann Healthcare Conference<\/b>
\n July 13-14<\/span>\n <\/p>\n

Presentation time:\u00a0 \u00a0 \u00a0 July 13, 2021<\/span> starting at 11:00am ET<\/span>
Webcast:\u00a0 \u00a0\u00a0 https:\/\/wsw.com\/webcast\/ladenburg7\/lpcn\/2414031<\/a>\u00a0<\/p>\n

The webcast of this presentation will also be available on Lipocine’s corporate website under “Events & Presentations” in the Investors section.\u00a0\u00a0<\/p>\n

\n About Lipocine Inc.<\/b>\n <\/p>\n

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males.\u00a0LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH.\u00a0LPCN 1144 is currently being studied in a Phase 2 clinical study.\u00a0 TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.\u00a0 For more information, please visit www.lipocine.com<\/a>.\u00a0 \u00a0<\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference-301320441.html<\/a><\/p>\n

SOURCE Lipocine Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SALT LAKE CITY, July 6, 2021 \/PRNewswire\/ —\u00a0Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually. Presentation details are below. Ladenburg Thalmann Healthcare Conference July 13-14 Presentation time:\u00a0 \u00a0 \u00a0 July 13, 2021 starting at 11:00am ETWebcast:\u00a0 \u00a0\u00a0 https:\/\/wsw.com\/webcast\/ladenburg7\/lpcn\/2414031\u00a0 The webcast of this presentation will also be available on Lipocine’s corporate website under “Events & Presentations” in the Investors section.\u00a0\u00a0 About Lipocine Inc. Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, … <\/p>\n

Continue reading “Lipocine To Present At The Ladenburg Thalmann Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-509670","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLipocine To Present At The Ladenburg Thalmann Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SALT LAKE CITY, July 6, 2021 \/PRNewswire\/ —\u00a0Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually. Presentation details are below. Ladenburg Thalmann Healthcare Conference July 13-14 Presentation time:\u00a0 \u00a0 \u00a0 July 13, 2021 starting at 11:00am ETWebcast:\u00a0 \u00a0\u00a0 https:\/\/wsw.com\/webcast\/ladenburg7\/lpcn\/2414031\u00a0 The webcast of this presentation will also be available on Lipocine’s corporate website under “Events & Presentations” in the Investors section.\u00a0\u00a0 About Lipocine Inc. Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, … Continue reading "Lipocine To Present At The Ladenburg Thalmann Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-06T12:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/627654\/Lipocine_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference\",\"datePublished\":\"2021-07-06T12:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/627654\\\/Lipocine_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/\",\"name\":\"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/627654\\\/Lipocine_Logo.jpg\",\"datePublished\":\"2021-07-06T12:04:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/627654\\\/Lipocine_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/627654\\\/Lipocine_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference - Market Newsdesk","og_description":"PR Newswire SALT LAKE CITY, July 6, 2021 \/PRNewswire\/ —\u00a0Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually. Presentation details are below. Ladenburg Thalmann Healthcare Conference July 13-14 Presentation time:\u00a0 \u00a0 \u00a0 July 13, 2021 starting at 11:00am ETWebcast:\u00a0 \u00a0\u00a0 https:\/\/wsw.com\/webcast\/ladenburg7\/lpcn\/2414031\u00a0 The webcast of this presentation will also be available on Lipocine’s corporate website under “Events & Presentations” in the Investors section.\u00a0\u00a0 About Lipocine Inc. Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, … Continue reading \"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-06T12:04:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/627654\/Lipocine_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference","datePublished":"2021-07-06T12:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/"},"wordCount":323,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/627654\/Lipocine_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/","name":"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/627654\/Lipocine_Logo.jpg","datePublished":"2021-07-06T12:04:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/627654\/Lipocine_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/627654\/Lipocine_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lipocine-to-present-at-the-ladenburg-thalmann-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lipocine To Present At The Ladenburg Thalmann Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=509670"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509670\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=509670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=509670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=509670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}